News on noninvasive prenatal testing, carrier screening, and preimplantation genetic screening.
The company said it will use the proceeds to increase commercialization of its PreTRM test, a blood biomarker test to determine the risk of premature delivery.
A preliminary analysis lends some support to covering NIPS for pregnancies beyond high-risk, and some payors have expanded coverage.
The company processed more than 200,000 tests during the quarter, an increase of 20 percent compared to the 167,000 tests it processed in Q3 of last year.
The company said three clinical centers have validated the test in a prospective clinical trial involving more than 10,000 participants.
The Unity test enables screening for several autosomal recessive conditions from fetal DNA gathered from maternal blood.
